Skip to main content
TRAW
NASDAQ Life Sciences

Traws Pharma Reports Positive Phase 2 Ratutrelvir Data for COVID-19 and Expands Tivoxavir Marboxil Program for Influenza Prophylaxis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.44
Mkt Cap
$19.338M
52W Low
$0.97
52W High
$8.61
52W Position info
152% above low
Off High info
72% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TRAW has more than doubled off its 52-week low of $0.97 on light trading volume (0.2× avg).

Summary

Traws Pharma announced the completion of enrollment and positive preliminary results for its Phase 2 COVID-19 study of ratutrelvir, while also revealing plans to develop tivoxavir marboxil as a prophylactic treatment for seasonal influenza.


Key Events · Product Development and Regulatory · TRAW

  • Ratutrelvir Phase 2 Enrollment Complete

    Traws Pharma completed enrollment in its 90-patient, open-label Phase 2 study of ratutrelvir for mild-to-moderate COVID-19, including a arm for PAXLOVID-ineligible patients.

  • Positive Preliminary Ratutrelvir Data

    Ongoing data analysis confirms ratutrelvir's differentiated profile with fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution, including in PAXLOVID-ineligible patients.

  • Tivoxavir Marboxil Expanded Indication

    The company is progressing tivoxavir marboxil (TXM) as a single monthly oral tablet for the prophylactic treatment of seasonal influenza, aiming for 28-day protection.

  • Influenza Challenge Study Secured

    A human influenza prophylaxis challenge study time slot has been secured for June 2026 to advance TXM into registration studies.


Analysis · TRAW · Life Sciences

This filing provides significant positive updates on Traws Pharma's lead antiviral programs. The completion of enrollment and preliminary positive data for ratutrelvir in a Phase 2 COVID-19 study, particularly its differentiated profile and efficacy in PAXLOVID-ineligible patients, suggests a strong potential for this candidate. Concurrently, the expansion of tivoxavir marboxil into a prophylactic treatment for seasonal influenza, with a secured challenge study, opens a new and substantial market opportunity. For a clinical-stage biopharmaceutical company of this size, these advancements represent critical value inflection points, potentially de-risking its pipeline and expanding its addressable markets.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TRAW was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3M. The 52-week trading range was $0.97 to $8.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TRAW - Latest Insights

TRAW
Nov 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.252
Real-time Price: $0.244929 info
Change: -$0.007071 (-3%) info
Market Cap: $3.857M info
TRAW
Oct 26, 2026, 4:47 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.244929 info
Change: -$0.105071 (-30%) info
Market Cap: $3.857M info
TRAW
Oct 23, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3425
Real-time Price: $0.244929 info
Change: -$0.097571 (-28%) info
Market Cap: $3.857M info
TRAW
Oct 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3767
Real-time Price: $0.244929 info
Change: -$0.131771 (-35%) info
Market Cap: $3.857M info
TRAW
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4803
Real-time Price: $0.244929 info
Change: -$0.235371 (-49%) info
Market Cap: $3.857M info